Matinas BioPharma Holdings Inc Share Price Other OTC
Equities
US5768101058
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
09/05 | Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 44.04M 3.68B |
---|---|---|---|---|---|
Net income 2024 * | -25M -2.09B | Net income 2025 * | -34M -2.84B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.76
x | P/E ratio 2025 * |
-1.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.47% |
Latest transcript on Matinas BioPharma Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Jerome Jabbour
FOU | Founder | 50 | 01/13/01 |
Keith Kucinski
DFI | Director of Finance/CFO | 55 | 03/19/03 |
Hui Liu
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Herbert Conrad
FOU | Founder | 91 | 01/13/01 |
Natasha Giordano
BRD | Director/Board Member | 62 | 14/20/14 |
Eric Ende
CHM | Chairman | 55 | 03/17/03 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |